OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Yibo Yin, Alina C. Boesteanu, Zev A. Binder, et al.
Molecular Therapy — Oncolytics (2018) Vol. 11, pp. 20-38
Open Access | Times Cited: 149
Yibo Yin, Alina C. Boesteanu, Zev A. Binder, et al.
Molecular Therapy — Oncolytics (2018) Vol. 11, pp. 20-38
Open Access | Times Cited: 149
Showing 1-25 of 149 citing articles:
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner
Blood Cancer Journal (2021) Vol. 11, Iss. 4
Open Access | Times Cited: 1799
Robert C. Sterner, Rosalie M. Sterner
Blood Cancer Journal (2021) Vol. 11, Iss. 4
Open Access | Times Cited: 1799
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chenglong Chen, Lu Xie, Tingting Ren, et al.
Cancer Letters (2020) Vol. 500, pp. 1-10
Closed Access | Times Cited: 389
Chenglong Chen, Lu Xie, Tingting Ren, et al.
Cancer Letters (2020) Vol. 500, pp. 1-10
Closed Access | Times Cited: 389
Engineered cellular immunotherapies in cancer and beyond
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 210
Amanda Finck, Tatiana Blanchard, Christopher P. Roselle, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 678-689
Open Access | Times Cited: 210
CAR T cells for brain tumors: Lessons learned and road ahead
David Akhavan, Darya Alizadeh, Dongrui Wang, et al.
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 60-84
Open Access | Times Cited: 186
David Akhavan, Darya Alizadeh, Dongrui Wang, et al.
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 60-84
Open Access | Times Cited: 186
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Michael C. Burger, Congcong Zhang, Patrick N. Harter, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 178
Michael C. Burger, Congcong Zhang, Patrick N. Harter, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 178
Improving human cancer therapy through the evaluation of pet dogs
Amy K. LeBlanc, Christina Mazcko
Nature reviews. Cancer (2020) Vol. 20, Iss. 12, pp. 727-742
Closed Access | Times Cited: 150
Amy K. LeBlanc, Christina Mazcko
Nature reviews. Cancer (2020) Vol. 20, Iss. 12, pp. 727-742
Closed Access | Times Cited: 150
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Stephen Bagley, Meghan Logun, Joseph A. Fraietta, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1320-1329
Closed Access | Times Cited: 114
Stephen Bagley, Meghan Logun, Joseph A. Fraietta, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1320-1329
Closed Access | Times Cited: 114
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 2, pp. 192-209
Open Access | Times Cited: 108
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 2, pp. 192-209
Open Access | Times Cited: 108
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 105
Gunjan Dagar, Ashna Gupta, Tariq Masoodi, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 105
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions
Alaa Alnefaie, Sarah Albogami, Yousif A. Asiri, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 74
Alaa Alnefaie, Sarah Albogami, Yousif A. Asiri, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 74
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2388-2407.e9
Open Access | Times Cited: 74
Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2388-2407.e9
Open Access | Times Cited: 74
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Marco Ruella, Felix Korell, Patrizia Porazzi, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 976-995
Open Access | Times Cited: 60
Marco Ruella, Felix Korell, Patrizia Porazzi, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 12, pp. 976-995
Open Access | Times Cited: 60
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Arthur Xuan Wang, Xiao Jing Ong, Criselle D’Souza, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
Arthur Xuan Wang, Xiao Jing Ong, Criselle D’Souza, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression
Andrew S. Luksik, Eli Yazigi, Pavan P. Shah, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1414-1414
Open Access | Times Cited: 50
Andrew S. Luksik, Eli Yazigi, Pavan P. Shah, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1414-1414
Open Access | Times Cited: 50
Counteracting CAR T cell dysfunction
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, et al.
Oncogene (2020) Vol. 40, Iss. 2, pp. 421-435
Open Access | Times Cited: 118
Mansour Poorebrahim, Jeroen Melief, Yago Pico de Coaña, et al.
Oncogene (2020) Vol. 40, Iss. 2, pp. 421-435
Open Access | Times Cited: 118
CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma
Hui Liu, Wen Lei, Chaoting Zhang, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 2, pp. 473-484
Open Access | Times Cited: 105
Hui Liu, Wen Lei, Chaoting Zhang, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 2, pp. 473-484
Open Access | Times Cited: 105
Therapeutic potential of CAR T cell in malignancies: A scoping review
Ali Zarezadeh Mehrabadi, Reza Ranjbar, Mahdieh Farzanehpour, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112512-112512
Open Access | Times Cited: 89
Ali Zarezadeh Mehrabadi, Reza Ranjbar, Mahdieh Farzanehpour, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112512-112512
Open Access | Times Cited: 89
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Bas Weenink, Pim J. French, Peter A.E. Sillevis Smitt, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 751-751
Open Access | Times Cited: 87
Bas Weenink, Pim J. French, Peter A.E. Sillevis Smitt, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 751-751
Open Access | Times Cited: 87
A Role for Dogs in Advancing Cancer Immunotherapy Research
Steven Dow
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 84
Steven Dow
Frontiers in Immunology (2020) Vol. 10
Open Access | Times Cited: 84
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84
Adham S. Bear, Tatiana Blanchard, Joseph Cesare, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 84
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Niels Schaft
Cancers (2020) Vol. 12, Iss. 9, pp. 2567-2567
Open Access | Times Cited: 82
Niels Schaft
Cancers (2020) Vol. 12, Iss. 9, pp. 2567-2567
Open Access | Times Cited: 82
Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy
Hongsheng Wang, Huangao Zhou, Jianing Xu, et al.
Cancer Letters (2020) Vol. 496, pp. 134-143
Open Access | Times Cited: 74
Hongsheng Wang, Huangao Zhou, Jianing Xu, et al.
Cancer Letters (2020) Vol. 496, pp. 134-143
Open Access | Times Cited: 74
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia
Michelle J. Cox, Fabrice Lucien, Reona Sakemura, et al.
Molecular Therapy (2021) Vol. 29, Iss. 4, pp. 1529-1540
Open Access | Times Cited: 62
Michelle J. Cox, Fabrice Lucien, Reona Sakemura, et al.
Molecular Therapy (2021) Vol. 29, Iss. 4, pp. 1529-1540
Open Access | Times Cited: 62
Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors
Yibo Yin, Jesse L. Rodriguez, Nannan Li, et al.
Molecular Therapy (2022) Vol. 30, Iss. 7, pp. 2537-2553
Open Access | Times Cited: 61
Yibo Yin, Jesse L. Rodriguez, Nannan Li, et al.
Molecular Therapy (2022) Vol. 30, Iss. 7, pp. 2537-2553
Open Access | Times Cited: 61
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Hongwen Li, Wenting Song, Zhaoming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 60
Hongwen Li, Wenting Song, Zhaoming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 60
